GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (NYSE:EW) » Definitions » Debt-to-Equity
中文

Edwards Lifesciences (Edwards Lifesciences) Debt-to-Equity : 0.10 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Edwards Lifesciences Debt-to-Equity?

Edwards Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $25 Mil. Edwards Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $670 Mil. Edwards Lifesciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6,650 Mil. Edwards Lifesciences's debt to equity for the quarter that ended in Dec. 2023 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Edwards Lifesciences's Debt-to-Equity or its related term are showing as below:

EW' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1   Med: 0.18   Max: 0.35
Current: 0.1

During the past 13 years, the highest Debt-to-Equity Ratio of Edwards Lifesciences was 0.35. The lowest was 0.10. And the median was 0.18.

EW's Debt-to-Equity is ranked better than
66.9% of 713 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs EW: 0.10

Edwards Lifesciences Debt-to-Equity Historical Data

The historical data trend for Edwards Lifesciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Debt-to-Equity Chart

Edwards Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.15 0.12 0.12 0.10

Edwards Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.11 0.10 0.10

Competitive Comparison of Edwards Lifesciences's Debt-to-Equity

For the Medical Devices subindustry, Edwards Lifesciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Debt-to-Equity falls into.



Edwards Lifesciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Edwards Lifesciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Edwards Lifesciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edwards Lifesciences  (NYSE:EW) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Edwards Lifesciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences (Edwards Lifesciences) Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Executives
Bobo Donald E Jr officer: CVP,Strategy/Corp Development C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Michael A Mussallem director, officer: Chairman & CEO C/O EDWARDS LIFESCIENCES CORP, ONE EDWARDS WAY, IRVINE CA 92614
Scott B. Ullem officer: CVP, CFO C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Daveen Chopra officer: CVP, Surgical Structural Heart C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92618
Larry L Wood officer: CVP, THV Replacement C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Catherine M. Szyman officer: CVP, Critical Care C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Wayne Markowitz officer: GM & SVP, Surgical ONE EDWARDS WAY, IRVINE CA 92614
Heisz Leslie Stone director C/O PUBLIC STORAGE, 701 WESTERN AVENUE, GLENDALE CA 91201
Jean-luc M Lemercier officer: CVP, EMEA, Canada, Latin Amer C/O ONE EDWARDS WAY, IRVINE CA 92614
Sellers Robert W.a. officer: VP, Corp. Controller (Principa ONE EDWARDS WAY, IRVINE CA 92614
Bernard J Zovighian officer: CVP, Surgical Heart Valves C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Huimin Wang officer: CVP, Japan & Intercontinental C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Martha H. Marsh director 9769 WEXFORD CIRCLE, GRANITE BAY CA 95746
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614